Cohort 2 for Stage IV Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Memorial Sloan Kettering Cancer Center, New York, NY
Stage IV Non-small Cell Lung Cancer+6 More
IOV-4001 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Eligible Conditions

  • Stage IV Non-small Cell Lung Cancer
  • Unresectable Melanoma
  • Stage III Non-small Cell Lung Cancer
  • Metastatic Melanoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Stage IV Non-small Cell Lung Cancer

Study Objectives

2 Primary · 7 Secondary · Reporting Duration: Up to 1 Year or depending on when the recommended phase 2 dose is determined

Year 1
Phase I: Safety of IOV-4001
Up to 60 months
CR Rate
Disease Control Rate (DCR)
Duration of Response (DOR)
Feasibility of IOV-4001
Overall Survival (OS)
Phase 2: Objective Response Rate (ORR)
Progression-free Survival (PFS)
Safety and Tolerability of IOV-4001

Trial Safety

Safety Progress

1 of 3

Other trials for Stage IV Non-small Cell Lung Cancer

Trial Design

2 Treatment Groups

Cohort 2
1 of 2
Cohort 1
1 of 2
Experimental Treatment

53 Total Participants · 2 Treatment Groups

Primary Treatment: Cohort 2 · No Placebo Group · Phase 1 & 2

Cohort 2
Biological
Experimental Group · 1 Intervention: IOV-4001 · Intervention Types: Biological
Cohort 1
Biological
Experimental Group · 1 Intervention: IOV-4001 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year or depending on when the recommended phase 2 dose is determined
Closest Location: Memorial Sloan Kettering Cancer Center · New York, NY
Photo of Memorial Sloan Kettering Cancer Center  1Photo of Memorial Sloan Kettering Cancer Center  2Photo of Memorial Sloan Kettering Cancer Center  3
2011First Recorded Clinical Trial
1 TrialsResearching Stage IV Non-small Cell Lung Cancer
949 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma (Cohort 1) or Stage III or IV NSCLC (Cohort 2).
Cohort 1 (melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhibitor in those with BRAF mutations.
You have an ECOG performance status of 0 or 1.
You have at least one measurable lesion following resection of the lesion for IOV-4001 generation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.